PTIのチャート
PTIの企業情報
| symbol | PTI |
|---|---|
| 会社名 | Pain Therapeutics Inc （ペイン・セラピュ―ティックス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Proteostasis Therapeutics Inc. is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network a set of pathways that control protein biosynthesis folding trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models. Using this platform it has identified a new class of small molecules amplifiers that modulate proteins in the proteostasis network. It is developing and intend to commercialize its lead amplifier of CFTR protein PTI-428 to improve CFTR protein function. It also focuses on developing PTI-NC-733 PTI-130 Usp14 program and unfolded protein response (UPR) program. PTI-130 is a small molecule amplifier. ペイン・セラピュ―ティックスは米国のバイオ医薬品企業。薬剤候補は経口カプセル剤の鎮痛剤「レモクシ―(REMOXY)」。「レモクシ―」はオキシコドンを含むゼラチン・カプセル剤で、1日に2回の服用で長時間作用する。同社は、ファイザ―の子会社であるキング・ファ―マシュ―ティカルズと新薬開発を提携する。本社はテキサス州オ―スティン。 |
| 本社所在地 | 7801 N. Capital of Texas Highway Suite 260 Austin TX 78731 USA |
| 代表者氏名 | M. James Barrett M.ジェームズ・バレット |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 617-225-0096 |
| 設立年月日 | 35916 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2016年 |
| 従業員数 | － |
| url | www.paintrials.com |
| nasdaq_url | https://www.nasdaq.com/symbol/pti |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -53.39700 |
| 終値（lastsale） | 1.98 |
| 時価総額（marketcap） | 72659957.04 |
| 時価総額 | 時価総額（百万ドル） 291.74080 |
| 売上高 | 売上高（百万ドル） 4.95800 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 230.92080 |
| 当期純利益 | 当期純利益（百万ドル） -53.88200 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Proteostasis Therapeutics Inc revenues decreased 18% to $1.8M. Net loss decreased 17% to $26.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Research and Development - Balancing decrease of 27% to $20.2M (expense) Other income (expense) net increase from $32K (expense) to $136K (income). |
PTIのテクニカル分析
PTIのニュース
Phoenix Tower International recognized for the "Latin American Loan of the Year" by 2022 IFR Awards 2023/04/11 16:00:00 Kwhen Finance
Imran Khan: Former Pakistani PM attends first rally since shooting 2022/11/26 15:51:49 Kwhen Finance
Phoenix Tower International recognized for the "Latin American Loan of the Year" by 2022 IFR Awards 2023/04/11 16:00:00 Kwhen Finance
Imran Khan: Former Pakistani PM attends first rally since shooting 2022/11/26 15:51:49 Kwhen Finance